VIDEO: Phase 2 data show IOP reduction for 1 year with iDose

SAN FRANCISCO — At the Glaucoma 360: New Horizons Forum, L. Jay Katz, MD, chief medical officer at Glaukos, discusses phase 2 data for the company’s iDose device, which releases a continuous dose of travoprost.

SAN FRANCISCO — At the Glaucoma 360: New Horizons Forum, L. Jay Katz, MD, chief medical officer at Glaukos, discusses phase 2 data for the company’s iDose device, which releases a continuous dose of travoprost.